NBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
NovaBridge Biosciences
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026
$1.30+0.04 (+3.17%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2023 Ended Dec 31, 2023 | Mar 15, 2024 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 30, 2022 | Before market open | – | – | – |
Press releases
Announcements NovaBridge Biosciences filed with the SEC
As of June 30, 2026 and December 31, 2025
EX-99.2 to Form 6-K
Company Presentation NASDAQ: NBP August 2026
EX-99.1 to Form 6-K
NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026
EX-99.1 to Form 6-K
(Incorporated in the Cayman Islands with limited liability)
EX-99.2 to Form 6-K
(Incorporated in the Cayman Islands with limited liability)
EX-99.3 to Form 6-K
2026 OMNIBUS SHARE INCENTIVE PLAN
EX-99.1 to Form 6-K
NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer
EX-99.1 to Form 6-K
VIS-101 Phase 2a Update Clinical Results and Next Steps March 9, 2026
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
NovaBridge Biosciences Supplemental and Updated Disclosures
EX-99.1 to Form 6-K
2440 Research Boulevard, Suite 400
EX-99.1 to Form 6-K
2440 Research Boulevard, Suite 400
EX-99.2 to Form 6-K
P R O X Y
EX-99.3 to Form 6-K